Grant Hawthorne

NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.

Auspherix Ltd. operates as an early stage anti-infectives company which develops novel antibiotics to treat resistant bacterial diseases. The firm uses a library screening approach to identify drugs with novel mechanisms of action as antibiotics. The company was founded by Ian Charles and Dagmar Alber in 2013 and is headquartered in Stevenage, the United Kingdom.

Boundary Capital Partners LLP (Boundary Capital) is a venture capital firm founded in 2009. The firm is headquartered in London.